- Home
- CVBF vs TARS Comparison
CVBF vs TARS Comparison
Compare CVBF & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CVBF | TARS |
|---|---|---|
| Founded | 1974 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.7B |
| IPO Year | 2009 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CVBF | TARS |
|---|---|---|
| Price | $20.52 | $65.14 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | $24.50 | ★ $89.00 |
| AVG Volume (30 Days) | ★ 1.9M | 457.9K |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.95% | N/A |
| EPS Growth | 5.56 | ★ 48.21 |
| EPS | ★ 1.52 | N/A |
| Revenue | N/A | ★ $451,360,000.00 |
| Revenue This Year | $21.47 | $56.43 |
| Revenue Next Year | $15.21 | $30.19 |
| P/E Ratio | $13.26 | ★ N/A |
| Revenue Growth | N/A | ★ 146.71 |
| 52 Week Low | $17.95 | $38.51 |
| 52 Week High | $21.48 | $85.25 |
Technical Indicators
Market Signals| Indicator | CVBF | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 56.35 | 47.78 |
| Support Level | $19.84 | $61.24 |
| Resistance Level | $20.53 | $67.70 |
| Average True Range (ATR) | 0.48 | 3.18 |
| MACD | -0.03 | 0.04 |
| Stochastic Oscillator | 48.99 | 46.22 |
Price Performance
Historical ComparisonAbout CVBF CVB Financial Corporation
CVB Financial Corp is the holding company for Citizens Business Bank. Citizens Business Bank offers banking, lending, and investing services. It provides a full complement of lending products, including commercial, agribusiness, consumer, SBA, real estate, and construction loans, as well as equipment and vehicle leasing. Commercial products include lines of credit and other working capital financing, accounts receivable lending and letters of credit. It is a community bank with one reportable operating segment.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.